Big Pharma Using Mail-Order Pharmacies to Maintain High Prices

The United States has the dubious honor of paying the highest prescription drug costs in the world. Many healthcare economists attribute this to relatively lax cost regulation compared to other wealthy countries; however, a decade of insurers paying only for generic drugs when available and limiting drug choice in specific formularies has had little modulating effect. The most recent focus has been on the newer, very costly agents that have come to market. Targeted cancer therapies may be priced at $70,000-$115,000 per year, reformulated chemotherapeutics may also reach the six-figure level and the new hepatitis C therapies are major effective advances, but cost about $80,000 for a 12-week course. Unlike the above diseases, multiple sclerosis requires life-long treatment and the latest player, Plegridyis, is pegged at $62,000 per annum.

 

As opposed to being feted for prolonging life and easing suffering, the major pharmaceutical companies are being attacked for price gouging at the expense of the public. The industry has pushed back, citing that the 10% of healthcare dollars going to prescription drugs has been the same percentage since 1960. Moreover, they emphasize that drug development is long (10-15 years), rather inefficient as most formularies never get to market, and costly (about $1.3 billion). This investment in time and money is reflected in the final price of the medication. The arcana of drug pricing is beyond my pay grade, given the variables of the potential market, duration of therapy, efficacy of treatment, socioeconomics, and societal commitment to equitable healthcare. A simple, transparent and fair pricing system may be more utopian than feasible and the politics of effecting change is a maelstrom of special interests.

 

However, there is one villain trying to sidestep the barriers on pricing whom I find particularly reprehensible. Several small pharmaceutical manufacturers circumvent restraints by insurers and pharmacists to switch patients to generics by promoting mail-order pharmacies affiliated with the drug company. The high-priced drugs are delivered quickly and copays are subsidized and because some insurers will pay the often exorbitant charges, the scheme is economically viable. Here are examples-- Horizon Pharma has a pain reliever, Duexis, which contains two generic equivalents of Motrin and Pepcid. It is targeted to patients as offsetting the gastrointestinal side effects of the NSAID.  Daily Duexis therapy costs about $1500/month, while the two drugs sold separately cost $20-$40/month as generics or OTC. The company says that combining the drugs into a single pill taken three times daily makes compliance more likely as patients will get the benefit of stomach protection. Valeant Pharmaceuticals does much the same thing for its dermatology products with its specialty pharmacy Philidor Rx Services

 

This is sophistry at its finest. Fortunately these attempts of dampening the sticker shock of using these drugs have caused many benefit managers to refuse all payment for these products. Moreover, these companies have also received subpoenas from federal prosecutors in New York and Massachusetts seeking more information on their pricing practices. Of more immediate harm, investors have seen the light as Valeant’s market capitalization has decreased 70% since August. This all begs the question: who writes these prescriptions and why? We do, and I cannot think why.

 

By Norman Silverman, MD, with Ryan McKennon, DO and Ren Carlton

 

Cutting Healthcare Spending - Big Data, Hospital Costs, and Outcomes

According to the federal Agency for Healthcare Research and Quality (AHRQ), inpatient hospital costs account for nearly 30% of healthcare spending in the United States and are increasing by about 2% per year over inflation. This cost issue is a focus of the Affordable Care Act, which is accelerating the move away from fee-for-service to a single, diagnosis-related comprehensive payment, similar to Medicare reimbursement. Such payment systems punish unnecessary testing, prolonged hospitalization, and readmissions.

Is Medical Science Dead? - Art, Science, and Quackery

On April 8, 1966, Time Magazine caused a national commotion when the issue’s cover was emblazoned with the question, “Is God Dead?” The Time article was a measured consideration of how society was adapting to the diminishing role of religion in an age of stunning scientific advances. The writer posited that people would no longer believe things out of received doctrine, but faith would steadily succumb to the scientific method as mankind unraveled the truths of the physical world at the expense of the myths of the metaphysical.

IMPACT OF ICD-10 - Increases Billing Accuracy, Headache for MDs and Patients

I strongly suggest that a pledge to read a synopsis of the philosophy of the 13th century Franciscan William of Ockham on a weekly basis be inserted in the oath of office taken by every government employee. Clearly highlighted should be his nominalist doctrine, Ockham’s razor, which avows that the best solution to a problem is usually the simplest. Pare to a minimum the number of confounding variables.

How do we treat pain? - Unrealistic Goals Leading to Opioid Addiction

In the weekend review from ACEP, two articles caught my attention. The first one was on new guidelines from the American Society of Addictive Medicine on the use of prescription medication to treat opioid addiction. These guidelines were created soon after the Centers for Disease Control and Prevention (CDCP) declared opioid use and resultant death as an epidemic. The second article refers to a study showing that pain is underdiagnosed and undertreated in the ED. This is the challenging dichotomy we live and work in.

Drowning in the Fountain of Youth - Genetic Predisposition

Recently I read in a New York Times magazine article that the 130th richest man in the United States wants to match his age with his Forbes magazine wealth ranking. His riches have not bought him a unique, scientifically-formulated elixir for immortality; nor is he a wacky proponent of perpetual hyperbaric oxygen chambers or cryogenics.

Yelp May Not Help

Concomitant with the metamorphosis of the practice of medicine into the business of healthcare delivery, patients have been transformed into customers. Healthcare providers compete not only on the basis of outcomes, best practices, centers of excellence, advanced technology and cost, but also on customer service

Find and Replace: Genetic Engineering in Science and Medicine

Shakespeare’s Hamlet proclaimed, “What a piece of work is a man,” but now, almost half a millennium later, this could be amended to what a set of sequences is man. The nobility, reason, infinite faculty and admirable form can be attributed to the 20,000 or so genes that contain the chemical code for specific protein formation

HIPAA Protects Millions with Unintended Consequences

The Health Insurance Portability and Accountability Act (HIPAA) was endorsed by Congress in 1996 and was the last significant legislative legacy of Senator Ted Kennedy. It is enforced by the Office for Civil Rights and mandates nationally recognized regulations for use and/or disclosure of an individual's health information by a “covered entity”. Such an entity is a health plan, healthcare clearinghouse or healthcare provider.

Studies Prove Communication and Teambuilding Training a MUST for Surgical And Hospital Staff

Although individual judgment and technical dexterity are obviously important, best surgical outcomes, particularly for complex procedures, reflect the performance of many medical providers before, during and after an operation. Professionalism and a competitive business environment both stimulate medical centers to continuously focus on quality assurance programs, and to improve patient safety.

Death Rates Plunge Due to Following Protocols, Not New Technology

We are regaled in the lay press about new medical breakthroughs a novel cholesterol-lowering drug mimics the effects of a genetic mutation and improves lipid profiles when conventional treatment is ineffective; new cancer therapies are tailored medications designed to specifically attack tumor cells without the nonspecific toxicity of conventional chemotherapy; hepatitis C can be cured by short-term oral agents, not prolonged courses of parenteral infusions; mitral valves can be repaired percutaneously without the potential risks of extracorporeal circulation.

How to Grow Your Medical Practice Online

Here at Michigan Physicians Society, we’re dedicated to the financial betterment of physicians by providing continuing education and technology, along with an extensive network of other like-minded professionals in our space....
Page: 1234 - All